{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regimen+A&page=2",
    "query": {
      "intervention": "Regimen A",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 5974,
    "total_pages": 598,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regimen+A&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regimen+A&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T08:00:34.935Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02044341",
      "title": "Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Otitis Media"
      ],
      "interventions": [
        {
          "name": "AR01",
          "type": "DRUG"
        },
        {
          "name": "Glycerin ear drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arbor Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Months to 18 Years"
      },
      "enrollment_count": 304,
      "start_date": "2013-12",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-08",
      "last_synced_at": "2026-09-30T08:00:34.935Z",
      "location_count": 29,
      "location_summary": "Sheffield, Alabama • Tuscon, Arizona • Jonesboro, Arkansas + 25 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02044341"
    },
    {
      "nct_id": "NCT05043766",
      "title": "Evaluation of Oral PF614 Relative to OxyContin (PF614-102)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "PF614",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "OxyContin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ensysce Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 84,
      "start_date": "2021-09-08",
      "completion_date": "2022-03-21",
      "has_results": false,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-09-30T08:00:34.935Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05043766"
    },
    {
      "nct_id": "NCT03889418",
      "title": "Opioid Treatment and Recovery Through a Safe Pain Management Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depression",
        "Opioid Use",
        "Chronic Pain",
        "Anxiety"
      ],
      "interventions": [
        {
          "name": "Electronic medical recorded clinical decision support [EMR CDS]",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stepped opioid collaborative care model [CCM]",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Ochsner Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 490,
      "start_date": "2019-04-01",
      "completion_date": "2023-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-09-30T08:00:34.935Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03889418"
    },
    {
      "nct_id": "NCT02131766",
      "title": "USS Virginia Closed-Loop for Overnight Control in Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "DiAs",
          "type": "DEVICE"
        },
        {
          "name": "Sensor Augmented Pump Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 33,
      "start_date": "2014-06",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2020-04-16",
      "last_synced_at": "2026-09-30T08:00:34.935Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • New York, New York • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02131766"
    },
    {
      "nct_id": "NCT06153966",
      "title": "PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prion Disease"
      ],
      "interventions": [
        {
          "name": "ION717",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2024-01-04",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-09-30T08:00:34.935Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06153966"
    },
    {
      "nct_id": "NCT04117724",
      "title": "Antibiotic Adherence Practices in Dermatologic Surgery",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Medication Adherence"
      ],
      "interventions": [
        {
          "name": "Survey",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 276,
      "start_date": "2019-10-10",
      "completion_date": "2021-05-01",
      "has_results": false,
      "last_update_posted_date": "2021-08-30",
      "last_synced_at": "2026-09-30T08:00:34.935Z",
      "location_count": 9,
      "location_summary": "Davis, California • Indianapolis, Indiana • Minneapolis, Minnesota + 6 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04117724"
    },
    {
      "nct_id": "NCT00587054",
      "title": "Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allogeneic Stem Cell Transplant",
        "Leukemia",
        "Non-Hodgkins",
        "Lymphoblastic Lymphoma",
        "Myelodysplastic Syndrome",
        "Paroxysmal Nocturnal Hemoglobinuria (PNH)"
      ],
      "interventions": [
        {
          "name": "cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 129,
      "start_date": "2001-06",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-09-30T08:00:34.935Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00587054"
    },
    {
      "nct_id": "NCT00324805",
      "title": "Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stage IB Lung Non-Small Cell Carcinoma AJCC v7",
        "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7",
        "Stage IIB Lung Non-Small Cell Carcinoma AJCC v7",
        "Stage IIIA Lung Non-Small Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pemetrexed Disodium",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Vinorelbine Tartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1501,
      "start_date": "2007-07-19",
      "completion_date": "2025-01-31",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-09-30T08:00:34.935Z",
      "location_count": 1139,
      "location_summary": "Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 712 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00324805"
    },
    {
      "nct_id": "NCT06149403",
      "title": "A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "MPS-IH (Hurler Syndrome)"
      ],
      "interventions": [
        {
          "name": "Experimental: OTL-203",
          "type": "GENETIC"
        },
        {
          "name": "Active Comparator: Allo-HSCT",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Orchard Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": "30 Months",
        "sex": "ALL",
        "summary": "28 Days to 30 Months"
      },
      "enrollment_count": 41,
      "start_date": "2023-12-11",
      "completion_date": "2031-03",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-09-30T08:00:34.935Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06149403"
    },
    {
      "nct_id": "NCT02502266",
      "title": "Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Adenocarcinoma",
        "Fallopian Tube Serous Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fallopian Tube Undifferentiated Carcinoma",
        "Ovarian Clear Cell Adenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Ovarian Serous Adenocarcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Ovarian Undifferentiated Carcinoma",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cediranib",
          "type": "DRUG"
        },
        {
          "name": "Cediranib Maleate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Topotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 582,
      "start_date": "2016-05-03",
      "completion_date": "2027-03-04",
      "has_results": true,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-09-30T08:00:34.935Z",
      "location_count": 370,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Auburn",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02502266"
    }
  ]
}